Economic evaluation of Mectizan distribution

H. R. Waters, J. A. Rehwinkel, Gilbert M Burnham

Research output: Contribution to journalArticle

Abstract

The distribution of ivermectin has dramatically altered the nature of onchocerciasis control. Existing economic analyses of ivermectin distribution programmes show that these programmes have a highly beneficial impact. Most analyses have estimated the economic benefits in terms of increased labour productivity as a result of reductions in blindness, and in terms of additional land-availability because of a reduced transmission of the parasite. Economic evaluations of the Onchocerciasis Control Program (OPC) in West Africa have calculated a net present value - equivalent discounted benefits minus discounted costs - of $485 million for the programme over a 39-year period, using a conservative 10% rate to discount future health and productivity gains. The net present value for the African Program for Onchocerciasis Control (APOC) is calculated at $88 million over a 21-year time period, also using a 10% discount rate. Cost-effectiveness analyses of ivermectin distribution have found a cost of $14-$30 per disability-adjusted life-year prevented - estimates comparable with other priority disease control programmes. However, the economic success of ivermectin distribution is sensitive to the fact that the drug itself has been donated free of charge. The market value of Merck's donations to the APOC for just 1 year considerably outweighs the benefits calculated for both the OPC and the APOC over the life of these projects. Pending the development of an effective macrofilaricide, the distribution of ivermectin will remain a public health priority into the foreseeable future.

Original languageEnglish (US)
JournalTropical Medicine and International Health
Volume9
Issue number4
DOIs
StatePublished - Apr 2004

Fingerprint

Onchocerciasis
Ivermectin
Cost-Benefit Analysis
Economics
Costs and Cost Analysis
Health Priorities
Western Africa
Quality-Adjusted Life Years
Blindness
Parasites
Public Health
Health
Pharmaceutical Preparations

Keywords

  • Cost-benefit analysis
  • Cost-effectiveness analysis
  • Economic evaluation
  • Ivermectin
  • Mectizan
  • Onchocerciasis

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Infectious Diseases
  • Parasitology
  • Immunology

Cite this

Economic evaluation of Mectizan distribution. / Waters, H. R.; Rehwinkel, J. A.; Burnham, Gilbert M.

In: Tropical Medicine and International Health, Vol. 9, No. 4, 04.2004.

Research output: Contribution to journalArticle

@article{c6b2c2b1d27e4419839a3bfe7c029cc3,
title = "Economic evaluation of Mectizan distribution",
abstract = "The distribution of ivermectin has dramatically altered the nature of onchocerciasis control. Existing economic analyses of ivermectin distribution programmes show that these programmes have a highly beneficial impact. Most analyses have estimated the economic benefits in terms of increased labour productivity as a result of reductions in blindness, and in terms of additional land-availability because of a reduced transmission of the parasite. Economic evaluations of the Onchocerciasis Control Program (OPC) in West Africa have calculated a net present value - equivalent discounted benefits minus discounted costs - of $485 million for the programme over a 39-year period, using a conservative 10{\%} rate to discount future health and productivity gains. The net present value for the African Program for Onchocerciasis Control (APOC) is calculated at $88 million over a 21-year time period, also using a 10{\%} discount rate. Cost-effectiveness analyses of ivermectin distribution have found a cost of $14-$30 per disability-adjusted life-year prevented - estimates comparable with other priority disease control programmes. However, the economic success of ivermectin distribution is sensitive to the fact that the drug itself has been donated free of charge. The market value of Merck's donations to the APOC for just 1 year considerably outweighs the benefits calculated for both the OPC and the APOC over the life of these projects. Pending the development of an effective macrofilaricide, the distribution of ivermectin will remain a public health priority into the foreseeable future.",
keywords = "Cost-benefit analysis, Cost-effectiveness analysis, Economic evaluation, Ivermectin, Mectizan, Onchocerciasis",
author = "Waters, {H. R.} and Rehwinkel, {J. A.} and Burnham, {Gilbert M}",
year = "2004",
month = "4",
doi = "10.1111/j.1365-3156.2004.01210.x",
language = "English (US)",
volume = "9",
journal = "Tropical Medicine and International Health",
issn = "1360-2276",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Economic evaluation of Mectizan distribution

AU - Waters, H. R.

AU - Rehwinkel, J. A.

AU - Burnham, Gilbert M

PY - 2004/4

Y1 - 2004/4

N2 - The distribution of ivermectin has dramatically altered the nature of onchocerciasis control. Existing economic analyses of ivermectin distribution programmes show that these programmes have a highly beneficial impact. Most analyses have estimated the economic benefits in terms of increased labour productivity as a result of reductions in blindness, and in terms of additional land-availability because of a reduced transmission of the parasite. Economic evaluations of the Onchocerciasis Control Program (OPC) in West Africa have calculated a net present value - equivalent discounted benefits minus discounted costs - of $485 million for the programme over a 39-year period, using a conservative 10% rate to discount future health and productivity gains. The net present value for the African Program for Onchocerciasis Control (APOC) is calculated at $88 million over a 21-year time period, also using a 10% discount rate. Cost-effectiveness analyses of ivermectin distribution have found a cost of $14-$30 per disability-adjusted life-year prevented - estimates comparable with other priority disease control programmes. However, the economic success of ivermectin distribution is sensitive to the fact that the drug itself has been donated free of charge. The market value of Merck's donations to the APOC for just 1 year considerably outweighs the benefits calculated for both the OPC and the APOC over the life of these projects. Pending the development of an effective macrofilaricide, the distribution of ivermectin will remain a public health priority into the foreseeable future.

AB - The distribution of ivermectin has dramatically altered the nature of onchocerciasis control. Existing economic analyses of ivermectin distribution programmes show that these programmes have a highly beneficial impact. Most analyses have estimated the economic benefits in terms of increased labour productivity as a result of reductions in blindness, and in terms of additional land-availability because of a reduced transmission of the parasite. Economic evaluations of the Onchocerciasis Control Program (OPC) in West Africa have calculated a net present value - equivalent discounted benefits minus discounted costs - of $485 million for the programme over a 39-year period, using a conservative 10% rate to discount future health and productivity gains. The net present value for the African Program for Onchocerciasis Control (APOC) is calculated at $88 million over a 21-year time period, also using a 10% discount rate. Cost-effectiveness analyses of ivermectin distribution have found a cost of $14-$30 per disability-adjusted life-year prevented - estimates comparable with other priority disease control programmes. However, the economic success of ivermectin distribution is sensitive to the fact that the drug itself has been donated free of charge. The market value of Merck's donations to the APOC for just 1 year considerably outweighs the benefits calculated for both the OPC and the APOC over the life of these projects. Pending the development of an effective macrofilaricide, the distribution of ivermectin will remain a public health priority into the foreseeable future.

KW - Cost-benefit analysis

KW - Cost-effectiveness analysis

KW - Economic evaluation

KW - Ivermectin

KW - Mectizan

KW - Onchocerciasis

UR - http://www.scopus.com/inward/record.url?scp=2342652220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342652220&partnerID=8YFLogxK

U2 - 10.1111/j.1365-3156.2004.01210.x

DO - 10.1111/j.1365-3156.2004.01210.x

M3 - Article

C2 - 15078276

AN - SCOPUS:2342652220

VL - 9

JO - Tropical Medicine and International Health

JF - Tropical Medicine and International Health

SN - 1360-2276

IS - 4

ER -